Abstract
The use of voriconazole, a trifluorinated antifungal, has been associated with the development of fluoride excess and periostitis/ exostoses. We evaluated a cohort of patients on long-term triazole therapy and found that other fluorinated triazoles (fluconazole and posaconazole) conferred no risk for the development of hyperfluorosis and its complications in our cohort.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 563-564 |
| Number of pages | 2 |
| Journal | Antimicrobial Agents and Chemotherapy |
| Volume | 56 |
| Issue number | 1 |
| DOIs | |
| State | Published - Jan 2012 |
Fingerprint
ASJC Scopus subject areas
- Pharmacology (medical)
- Pharmacology
- Infectious Diseases
Cite this
Fluoride excess in coccidioidomycosis patients receiving long-term antifungal therapy : An assessment of currently available triazoles. / Thompson, George Richard; Bays, Derek; Cohen, Stuart H; Pappagianis, Demosthenes.
In: Antimicrobial Agents and Chemotherapy, Vol. 56, No. 1, 01.2012, p. 563-564.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Fluoride excess in coccidioidomycosis patients receiving long-term antifungal therapy
T2 - An assessment of currently available triazoles
AU - Thompson, George Richard
AU - Bays, Derek
AU - Cohen, Stuart H
AU - Pappagianis, Demosthenes
PY - 2012/1
Y1 - 2012/1
N2 - The use of voriconazole, a trifluorinated antifungal, has been associated with the development of fluoride excess and periostitis/ exostoses. We evaluated a cohort of patients on long-term triazole therapy and found that other fluorinated triazoles (fluconazole and posaconazole) conferred no risk for the development of hyperfluorosis and its complications in our cohort.
AB - The use of voriconazole, a trifluorinated antifungal, has been associated with the development of fluoride excess and periostitis/ exostoses. We evaluated a cohort of patients on long-term triazole therapy and found that other fluorinated triazoles (fluconazole and posaconazole) conferred no risk for the development of hyperfluorosis and its complications in our cohort.
UR - http://www.scopus.com/inward/record.url?scp=84455192484&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84455192484&partnerID=8YFLogxK
U2 - 10.1128/AAC.05275-11
DO - 10.1128/AAC.05275-11
M3 - Article
C2 - 22005993
AN - SCOPUS:84455192484
VL - 56
SP - 563
EP - 564
JO - Antimicrobial Agents and Chemotherapy
JF - Antimicrobial Agents and Chemotherapy
SN - 0066-4804
IS - 1
ER -